<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR320.html">Part 320
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 320.30  Inquiries regarding bioavailability and bioequivalence
                            </h3>
                            <p class="depth1"><em>(a)</em> The Commissioner of Food and Drugs strongly recommends that, to  avoid the conduct of an improper study and unnecessary human research,  any person planning to conduct a bioavailability or bioequivalence study  submit the proposed protocol for the study to FDA for review prior to  the initiation of the study.</p><p class="depth1"><em>(b)</em> FDA may review a proposed protocol for a bioavailability or  bioequivalence study and will offer advice with respect to whether the  following conditions are met:</p><p class="depth2"><em>(1)</em> The design of the proposed bioavailability or bioequivalence  study is appropriate.</p><p class="depth2"><em>(2)</em> The reference material to be used in the bioavailability or  bioequivalence study is appropriate.</p><p class="depth2"><em>(3)</em> The proposed chemical and statistical analytical methods are  adequate.</p><p class="depth1"><em>(c)</em></p><p class="depth2"><em>(1)</em> General inquiries relating to in vivo bioavailability  requirements and methodology shall be submitted to the Food and Drug  Administration, Center for Drug Evaluation and Research, Office of  Clinical Pharmacology, 10903 New Hampshire Ave., Silver Spring, MD  20993-0002.</p><p class="depth2"><em>(2)</em> General inquiries relating to bioequivalence requirements and  methodology shall be submitted to the Food and Drug Administration,  Center for Drug Evaluation and Research, Division of Bioequivalence  (HFD-650), 7500 Standish Pl., Rockville, MD 20855-2773.  [57 FR 18000, Apr. 28, 1992, as amended at 67 FR 77674, Dec. 19, 2002;  74 FR 13114, Mar. 26, 2009]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
